1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
ABL Bio Inc.

ABL Bio Inc.

298380.KQ
ABL Bio Inc.KR flagKOSDAQ
107,100.00
KRW
-4,800.00
- -
5.90TMarket Cap
ABL Bio Inc.
298380.KQ
(KOSDAQ)

Recent

price

107,100.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
3.7
40.82
88.18
175.91
113.48
1,405.32
1,362.13
695.38
1,540.55
1,716.26
Revenue per Share
-72,327.06
-3,874
-3,804
-818
-1,207
-927
67
-55
-1,156
-734
-458.63
Basic EPS, GAAP
-27,716.01
-418.88
-453.81
-612.18
-1,040.29
-891.1
1,430.25
-710.84
-1,633.38
-1,202.23
122.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-71,817.33
-4,581.99
-5,950.91
-4,877.18
-5,989.55
-6,788.39
-6,582.58
-6,616.6
-7,789.26
-7,933.87
-8,032.06
Book Value per Share
-65,373.56
-4,474.75
5,076.64
2,857.22
1,909.22
1,136.4
1,397.02
1,486.77
3,372.49
2,986.54
3,426.45
Tangible Book Value per Share
- -
19
31
45
46
47
48
48
48
52
53
Basic Weighted Avg Shares
- -
71
1,258
3,989
8,104
5,332
67,301
65,547
33,403
79,350
90,321
Sales/Revenue/Turnover
- -
-13,512.44
-1,910.82
-1,014.19
-736.04
-960.06
1.35
-4.01
-177.56
-50.76
-31.52
Operating Margin (%)
176
404
621
1,648
2,064
2,158
2,325
2,590
2,410
3,449
3,860
Depreciation Expense
-13,685
-74,734
-117,234
-37,005
-55,606
-43,558
3,209
-2,647
-55,529
-37,806
-24,136
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-104,628.08
-9,319.95
-927.68
-686.14
-816.91
4.77
-4.04
-166.24
-47.65
-26.72
Profit Margin (%)
5,392
8,093
149,505
125,330
63,951
36,722
8,362
33,779
80,791
52,553
79,539
Working Capital
- -
- -
- -
1,079
555
72
40,669
43,154
26
189
269
LT Debt
-12,099
-85,955
156,962
132,008
90,665
55,953
69,513
74,079
167,280
156,697
183,343
Total Equity
- -
- -
- -
- -
- -
- -
1.08
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-1.53
- -
- -
- -
6.56
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
43,185
55,138
55,223
LT Borrowings
- -
- -
- -
LT Finance Leases
290
189
269
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
55
- -
Market Capitalization
4,643,841
10,051,603
8,730,767

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
130,065
176,051
193,507
Cash, Cash Equivalents & STI
127,202
114,945
188,785
Accounts Receivable, Net
- -
59,112
- -
Inventories
- -
- -
- -
Total Current Liabilities
51,510
123,498
113,968
Payables & Accruals
- -
- -
- -
ST Debt
43,185
55,138
55,223
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
22.4%
-6.33%
Free Cash Flow
- -
-63.57%
-21.08%
Net Income, GAAP
- -
330.93%
-31.92%
Sales/Revenue/Turnover
- -
242.78%
137.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,937
8,442
7,937
9,087
33,403
2025
2,165
75,742
1,443
- -
79,350
2026
13,136
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-250
-238
-274
- -
-1,156
2025
-582
819.65
-394.77
- -
-734
2026
-261
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Raia Drogasil S.A. (RADL3.SA)
Praxsyn Corporation (PXYN)
Tsuruha Holdings Inc. (3391.T)
Cachet Pharmaceutical Co., Ltd. (002462.SZ)
ETHZilla Corporation Warrant (ATNFW)
Universal Health International Group Holding Limited (2211.HK)
Business
ABL Bio Inc. (298380.KQ) develops bispecific antibody therapeutics targeting immuno-oncology and neurodegenerative diseases; its Grabody platform enables blood-brain barrier shuttling via insulin-like growth factor 1 receptor targeting, 4-1BB agonist activation conditional on tumor antigens such as PD-L1 or ROR1 to minimize toxicity, and bispecific antibody-drug conjugates for rare blood cancers with optimized pharmacokinetics; key pipeline assets include ABL001 (tovecimig, VEGF x DLL4 for solid tumors, Phase 1/1b with U.S. FDA Fast Track), ABL111 (givastomig, Phase 1b data presented at ESMO GI 2025), ABL301 (SAR446159, transferring sponsorship to Sanofi), ABL503 (ragistomig, PD-L1 x 4-1BB, poster at ESMO IO), ABL105 (YH32367), ABL104 (YH32364), ABL202, ABL103, ABL102 (ROR1 x 4-1BB), ABL501 (PD-L1 x LAG-3), ABL602 (CLL1 bispecific T-cell engager for AML), and additional preclinical bispecific ADCs. Founded in 2016 and headquartered in Seongnam-si, South Korea, the company conducts clinical trials across the United States, China, Australia, and Korea, serving oncology and central nervous system patient populations with novel therapies to overcome PD-(L)1 resistance, enhance T-cell activation, and enable CNS drug delivery. In November 2025, ABL Bio entered a license, research, and collaboration agreement with Eli Lilly valued at up to $2.602 billion including a $40 million upfront for multiple Grabody-based therapeutics across modalities and areas like obesity and muscle diseases; it followed with a KRW 22 billion ($16 million) equity investment from Lilly via 175,079 shares at KRW 125,900 each to fund platform expansion and bispecific ADCs, pending U.S. antitrust approval; earlier, it signed a GSK licensing deal and launched U.S. spinout NEOK Bio with $75 million Series A for bispecific ADCs.